Document Type : Original Research

Authors

1 Student Committee Research, Babol University of Medical Sciences, Babol, Iran

2 Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

3 Clinical Research Development Center, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iran

10.30699/ijp.2020.114511.2245

Abstract

Background & Objective: Breast cancer is the most common malignancy in Iranian women and worldwide. Lymphatic vessel invasion (LVI) was found to be an independent prognostic factor in many carcinomas, including invasive carcinoma of the breast. The aim of this study was to compare the hematoxylin and eosin (H&E) staining method and the use of the immunohistochemistry (IHC) marker, D2-40, for evaluating LVI in breast carcinoma specimens.
Materials & Methods: The study was conducted on 50 patients undergone surgery between the years 2010 and 2015 in Rohani Hospital, Babol, Iran with invasive carcinoma of the breast with Census sampling method. LVI was assessed using H&E staining and two IHC markers, i.e., D2-40 and CD31, by two surgical pathologists.
 Results: LVI was detected in 25 (50%) patients by H&E and in 14 (28%) patients by D2-40. Twelve out of 25 patients with positive LVI in H&E were confirmed by D2-40 and 2 out of 25 patients with negative lymphatic vessel in H&E. Only one case showed weak staining of CD31 proving LVI. These results showed a significant difference between the H&E staining and D2-40 IHC study for LVI detection (p =0.004).
Conclusion: The D2-40 IHC marker is helpful in the diagnosis and confirmation of LVI in invasive carcinoma of the breast. CD31 is not suitable for the evaluation of lymphatic vessels.

Highlights

  • Lymphatic vessel invasion detected by H&E staining can have high false positive rate in breast carcinoma.
  • D2-40 IHC is useful in the identification of lymphatic vessel invasion in breast carcinoma.
  • CD31 IHC has no advantage for lymphatic vessel invasion assessment in breast carcinoma.

Keywords

Main Subjects

Nafissi N, Khayamzadeh M, Zeinali Z, Mohammadi G, Hosseini M, Akbari M. Breast Cancer in Iran, from Epidemiology, Clinicopathological and Biomarker Feature. Adv Biores. 2017;8(2).

Schiefer A-I, Schoppmann SF, Birner P. Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer. Surgery. 2016;160(2):331-40. [DOI:10.1016/j.surg.2016.02.034] [PMID]

Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Mod Pathol. 2011;24(4):502. [DOI:10.1038/modpathol.2010.199] [PMID]

Mohammed RA, Ellis IO, Elsheikh S, Paish EC, Martin SG. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat. 2009;113(2):261-73. [DOI:10.1007/s10549-008-9936-1] [PMID]

Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer. 2009;125(12):2747-56. [DOI:10.1002/ijc.24702] [PMID]

Teel P. VASCULAR INVASION AS A PROGNOSTIC FACTOR IN BREAST CARCINOMA. Surg Gynecol Obstet 1964;118:1006-8.

Mohammed RAA, Green A, El-Shikh S, Paish E, Ellis I, Martin S. Prognostic significance of vascular endothelial cell growth factors-A,-C and-D in breast cancer and their relationship with angio-and lymphangiogenesis. Br J Cancer. 2007;96(7):1092. [DOI:10.1038/sj.bjc.6603678] [PMID] [PMCID]

Lai J-H, Zhou Y-J, Bin D, Wang S-Y. Clinical significance of detecting lymphatic and blood vessel invasion in stage II colon cancer using markers D2-40 and CD34 in combination. Asian Pac J Cancer Prev. 2014;15(3):1363-7. [DOI:10.7314/APJCP.2014.15.3.1363] [PMID]

Debald M, Polcher M, Flucke U, Walgenbach-Brunagel G, Walgenbach KJ, Holler T, et al. Increased detection of lymphatic vessel invasion by D2-40 (podoplanin) in early breast cancer: possible influence on patient selection for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;77(4):1128-33. [DOI:10.1016/j.ijrobp.2009.06.088] [PMID]

De Mascarel I, MacGrogan G, Debled M, Sierankowski G, Brouste V, Mathoulin-Pélissier S, et al. D2-40 in breast cancer: should we detect more vascular emboli? Mod Pathol. 2009;22(2):216. [DOI:10.1038/modpathol.2008.151] [PMID]

Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166(3):913-21. [DOI:10.1016/S0002-9440(10)62311-5]

Heinzelbecker J, Kempf K-M, Kurz K, Steidler A, Weiss C, Jackson DG, et al., editors. Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: correlation with pathologic parameters and clinical outcome. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier. [DOI:10.1016/j.urolonc.2011.08.006] [PMID]

Radi DA, Abd-Elazeem MA. Prognostic Significance of Lymphatic Vessel Density Detected by D2-40 and Its Relation to Claudin-4 Expression in Prostatic Adenocarcinoma. Int J Surg Pathol. 2016;24(3):219-26. [DOI:10.1177/1066896915611488] [PMID]

Dileep A, Prasad P. Use of immunomarkers D2-40 and CD31 in detection of lymphovascular invasion in breast carcinoma. J Med Sci Clin Res. 2018;6:90-6. [DOI:10.18535/jmscr/v6i7.16]

Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670-80. [DOI:10.1002/cncr.26711] [PMID]

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9. [DOI:10.3322/caac.21388] [PMID]

Gujam FJ, Going JJ, Mohammed ZM, Orange C, Edwards J, McMillan DC. Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer. 2014;14(1):676. [DOI:10.1186/1471-2407-14-676] [PMID] [PMCID]

Mohammed RA, Menon S, Martin SG, Green AR, Paish EC, Ellis IO. Prognostic significance of lymphatic invasion in lymph node-positive breast carcinoma: findings from a large case series with long-term follow-up using immunohistochemical endothelial marker. Mod Pathol. 2014;27(12):1568. [DOI:10.1038/modpathol.2014.60] [PMID]

He KW, Sun JJ, Liu ZB, Zhuo PY, Ma QH, Liu ZY, et al. Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. Medicine (Baltimore). 2017;96(44):e8490. [DOI:10.1097/MD.0000000000008490] [PMID] [PMCID]

Shimizu K, Funai K, Sugimura H, Sekihara K, Kawase A, Shiiya N. D2‐40‐positive lymphatic vessel invasion is not a poor prognostic factor in stage I lung adenocarcinoma. Pathol int. 2013;63(4):201-5. [DOI:10.1111/pin.12048] [PMID]

Kitagawa Y, Ikebe D, Hara T, Kato K, Komatsu T, Kondo F, et al. Enhanced detection of lymphovascular invasion in small rectal neuroendocrine tumors using D2‐40 and Elastica van Gieson immunohistochemical analysis. Cancer Med. 2016;5(11):3121-7. [DOI:10.1002/cam4.935] [PMID] [PMCID]

Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007;20(2):183-91. [DOI:10.1038/modpathol.3800728] [PMID]

Dabbs DJ, editor. Diagnostic Immunohistochemistry E-Book: Theranostic and Genomic Applications. Elsevier Health Sciences; 2017 Nov 29.

Rabban JT, Chen YY. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol. 2008;39(2):175-83. [DOI:10.1016/j.humpath.2007.06.018] [PMID]